Nicole Germino
Stock Analyst at Truist Securities
(3.63)
# 820
Out of 5,124 analysts
23
Total ratings
65%
Success rate
35.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Nicole Germino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Buy | $126 → $139 | $174.04 | -20.13% | 10 | Aug 14, 2025 | |
| CATX Perspective Therapeutics | Maintains: Buy | $10 → $8 | $2.75 | +190.91% | 3 | May 14, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $5 | $0.42 | +1,090.48% | 5 | Jan 23, 2025 | |
| ASMB Assembly Biosciences | Downgrades: Hold | $132 → $24 | $34.01 | -29.43% | 3 | Oct 24, 2022 | |
| FBRX Forte Biosciences | Downgrades: Hold | n/a | $27.27 | - | 2 | Sep 3, 2021 |
Insmed
Aug 14, 2025
Maintains: Buy
Price Target: $126 → $139
Current: $174.04
Upside: -20.13%
Perspective Therapeutics
May 14, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $2.75
Upside: +190.91%
Sangamo Therapeutics
Jan 23, 2025
Maintains: Buy
Price Target: $7 → $5
Current: $0.42
Upside: +1,090.48%
Assembly Biosciences
Oct 24, 2022
Downgrades: Hold
Price Target: $132 → $24
Current: $34.01
Upside: -29.43%
Forte Biosciences
Sep 3, 2021
Downgrades: Hold
Price Target: n/a
Current: $27.27
Upside: -